It is estimated that prostate cancer will be diagnosed in nearly 268,000 men in 2022, making it the most commonly diagnosed cancer in men.1 Radiation therapy and surgical therapy are typically the primary treatment options for patients with prostate cancer. Options for radiation treatment include external beam radiation therapy (EBRT) and brachytherapy, wherein radioactive seeds are implanted into the prostate gland. EBRT has several modalities, based on regimen, with hypofractionated regimens called stereotactic beam radiation therapy (SBRT) delivering therapy over the shortest time. ...
GU Oncology Now Journal
A monthly publication highlighting original articles and interviews.
Articles from the Latest Issue
A review of a series of articles published by Urology on diversity, equity, and inclusion findings in prostate cancer care.
Studies on the use of cytoreductive nephrectomy in mRCC are reviewed, including its role among TKIs and immunotherapy.
A report examines the correlation between family history of prostate cancer and risk of progression after prostatectomy.
Dr. Stacy Loeb is interviewed on the use of active surveillance for prostate cancer, its history, and new insights.
Catherine Handy Marshall reviews her career from cardiovascular disease research to prostate cancer risk factors & genetics.
The utility of using AI to help determine scoring and surgical options for kidney cancer is examined against human scoring.